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The CD94-NKG2 receptor family that regulates
NKandTcells is uniqueamong the lectin-like re-
ceptors encoded within the natural killer cell
complex. The function of the CD94-NKG2 re-
ceptors is dictated by the pairing of the invariant
CD94 polypeptide with specific NKG2 isoforms
to form a family of functionally distinct heterodi-
meric receptors. However, the structural basis
for this selective pairing and how they interact
with their ligand, HLA-E, is unknown. We de-
scribe the 2.5 A˚ resolution crystal structure of
CD94-NKG2A inwhich themode of dimerization
contrasts with that of other homodimeric NK
receptors. Despite structural homology be-
tween the CD94 andNKG2A subunits, the dimer
interface is asymmetric, thereby providing a
structural basis for the preferred heterodi-
meric assembly. Structure-based sequence
comparisons of other CD94-NKG2 family mem-
bers, combined with extensive mutagenesis
studies on HLA-E and CD94-NKG2A, allows
a model of the interaction between CD94-
NKG2A and HLA-E to be established, in which
the invariant CD94 chain plays amore dominant
role in interacting with HLA-E in comparison to
the variable NKG2 chain.
INTRODUCTION
Natural killer (NK) cells play an important role in innate
immune responses to viral infection (Lodoen and Lanier,
2005). Their activity is regulated in part through an array
of activating and inhibitory receptors that recognize
MHC class Ia, class Ib, and class I-like molecules. These900 Immunity 27, 900–911, December 2007 ª2007 Elsevier Inreceptors include the killer cell immunoglobulin-like re-
ceptors (KIR), immunoglobulin-like transcripts ILT (Cella
et al., 2000), Ly49 receptors, and the more evolutionary
conserved receptors of the C-type lectin (NKC) superfam-
ily, including NKG2D and the CD94-NKG2 family (Borrego
et al., 2006). However, in stark contrast to the CD69,
NKG2D, and Ly49 family members, which are homodi-
meric receptors, CD94 is found as a heterodimer in vivo,
paired with specific members of the NKG2 receptor family
(Brooks et al., 1997; Carretero et al., 1997; Lazetic et al.,
1996; Li et al., 2001; Natarajan et al., 2000; Tormo et al.,
1999). Although a crystallographic CD94 homodimer has
been observed, the structural basis for the preferred
heterodimeric assembly of CD94-NKG2 receptors has
remained unclear.
Because CD94 lacks cytoplasmic signaling motifs, the
association of CD94 with NKG2 subunits is critical for
the biological activity of this family. Several members of
the NKG2 family including NKG2A, -2B, -2C, -2E, and -2H
dimerize with CD94 in vitro (Brostjan et al., 2002; Kaiser
et al., 2005; Lazetic et al., 1996). Moreover, there is evi-
dence that alternate mRNA splicing may generate addi-
tional isoforms of both inhibitory and activating receptors
(Houchins et al., 1997; Bello´n et al., 1999). NKG2A (and its
alternatively spliced variant NKG2B) contains cytoplasmic
ITIM motifs that are typical of inhibitory receptors in other
NK cell receptor families such as KIR (Houchins et al.,
1991). In contrast, NKG2E or -2H and NKG2C contain
a positively charged residue in their transmembrane
region that facilitates their association with the ITAM-con-
taining adaptor protein DAP-12 and hence appear to func-
tion as activating receptors (Lanier et al., 1998). However,
as with KIR, the in vivo role of activating isoforms of NKG2
remains unclear.
Human CD94-NKG2A as well as other human CD94-
NKG2 receptors recognize the class Ib molecule HLA-E
(Borrego et al., 1998; Braud et al., 1998a; Brooks et al.,
1999; Lee et al., 1998), whereas murine CD94-NKG2 re-
ceptors recognize the class Ib molecule Qa-1b (Vancec.
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The CD94-NKG2 Receptor Familyet al., 1998, 1999). The interaction of CD94-NKG2A with
HLA-E is a central mechanism by which NK cells indirectly
monitor the expression of other MHC class I molecules
within a target cell. Because HLA-E has evolved to bind
conserved sequences derived from their leader se-
quences of MHC-I, the optimal surface expression of
HLA-E is dependent on the expression of other MHC class
I molecules. In addition, because the loading of these pep-
tides into HLA-E requires proteasomal trimming and
a functional TAP, cell-surface expression of HLA-E may
represent a surrogate marker for functional antigen pro-
cessing necessary for the expression of other MHC class I
molecules (Bland et al., 2003; Braud et al., 1998b).
Here we report the structure of the CD94-NKG2A heter-
odimer, which reveals the basis for the preferred formation
of heterodimers within the CD94-NKG2 receptor family.
Moreover, the structure of the CD94-NKG2A receptor,
coupled with binding data assessing the interaction with
HLA-E, has permitted a model for the CD94-NKG2A inter-
action with HLA-E to be proposed.
RESULTS
Expression, Purification,
and Structure Determination
The extracellular region of CD94-NKG2A, which encom-
passed theC-type lectin domain and part of theN-terminal
stalk region for each protomer (NKG2A, residues 100–233;
CD94, residues 34–179), were expressed initially via a ba-
culovirus expression system. However, limited proteolysis
of the stalk regions, combined with glycosylation, resulted
in a recombinant CD94-NKG2A receptor that, although in-
teracting with HLA-E with similar affinity to that previously
reported (data not shown) (Kaiser et al., 2005; Vales-Go-
mez et al., 1999), was too heterogeneous for structural
studies. Consequently, the ectodomains of CD94 and
NKG2A, spanning residues 40–179 and 110–233, respec-
tively, were expressed in Eschericia coli and subsequently
refolded and purified to homogeneity. The E. coli-derived
CD94-NKG2A ectodomain interacted with HLA-E with
identical affinity to that of the baculovirus-derived CD94-
NKG2A, indicating that glycosylation of CD94-NKG2A is
not required for ligand recognition (data not shown). More-
over, reduced and nonreduced SDS-PAGE analysis re-
vealed that the baculovirus- and E. coli-derived CD94-
NKG2A behaved in a very similar manner, which included
evidence for the presence of an intermolecular disulfide
bond. Collectively, this indicated that the refolded CD94-
NKG2A receptor is a bona fide representative of the
CD94-NKG2A receptor found on the cell surface. The re-
folded CD94-NKG2A receptor crystallized in space group
P21, with unit cell dimensions a = 44.7 A˚, b = 34.7 A˚, c =
152.9 A˚, b = 89.7, with two heterodimers in the asymmet-
ric unit (Table 1). The structurewas subsequently refined to
2.5 A˚ resolution, to an Rfac and Rfree of 23.4% and 27.0%,
respectively. The final model comprises amino acids 57–
179 of CD94 and 113–232 of NKG2A, together with 51 wa-
termolecules (for clarity, NKG2AandCD94numbering has
the suffixes A and B, respectively). The two molecules inIthe asymmetric unit are virtually identical (root mean
square deviation [rmsd] 0.05 A˚), and structural analyses
will be confined to one molecule of the asymmetric unit.
The electron density at the dimer interface and the region
corresponding to the HLA-E binding site, with the excep-
tion of one small disordered region (residues 200A to
203A), was unambiguous, thereby permitting the salient
features of the CD94-NKG2A heterodimer to be analyzed.
Table 1. Data Collection and Refinement Statistics
Data Collection Statistics
Temperature (K) 100
X-ray source IMCA, APS
Detector Quantum 210 CCD
Space group P21
Cell dimensions (A˚) 44.7, 34.7, 152.9
Cell angles () 90, 89.7, 90
Resolution (A˚) 76.5-2.5 (2.64-2.5)
Total no. of
observations
52,441 (6,039)
No. of unique
observations
16,457 (2,242)
Multiplicity 3.2 (2.7)
Data completeness (%) 98.5 (93.6)
I/sI 10.1 (2.2)
Rsym
a (%) 12.2 (21.9)
Refinement Statistics
Nonhydrogen atoms
Protein 3871
Water 51
Resolution (A˚) 2.5
Rfactor
b (%) 23.4
Rfree
b (%) 27.0
Rmsd from ideality
Bond lengths (A˚) 0.009
Bond angles () 1.234
Ramachandran plot
Most favored (%) 85.6
Allowed regions (%) 14.4
B factors (A˚2)
Average protein 41.1
Average water
molecule
46.7
The values in parentheses are for the highest resolution bin
(approximate interval 0.1 A˚).
a Rsym = 100$S jIhkl  < Ihkl > j/SIhkl.
b Rfactor = 100$Shkl j jFoj  jFcj j/Shkl jFoj for all data except for
5%, which was used for the Rfree calculation.mmunity 27, 900–911, December 2007 ª2007 Elsevier Inc. 901
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The CD94-NKG2 Receptor FamilyFigure 1. NKG2A and the C-type Lectin Family
NKG2A has aC-type lectin fold as seen in NKG2D (Protein Data Bank ID code 1MPU), CD94 (1B6E), CD69 (1E8I), and Ly49A (1QO3). The b strands are
shown in blue and purple, the a helices in red, and disulfide bonds are in yellow. The secondary structure elements are labeled according to the CD94
nomenclature (Boyington et al., 1999).The NKG2A Subunit
The NKG2A monomer (Figure 1) possesses a meandering
N-terminal region (residues 113–118) that connects the
core of the molecule to the membrane-proximal stalk
region. The NKG2A ectodomain, with overall dimensions
54 3 33 3 29 A˚, comprises eight b strands that form
two b sheets at approximate right angles to each other,
and two a helices (residues 140–149 and 160–169) on
opposing faces of the protomer. The NKG2A fold is stabi-
lized by three disulfide bonds: Cys119–Cys130, bridging
the N-terminal loop and the b2 strand; Cys147–Cys229,
bridging a1 helix and b7 strand; and Cys208–Cys221,
that connects the b5 strand to loop 6.
As expected, the NKG2A fold is structurally homolo-
gous to the C-type lectins, and the comparative structural
analyses will be confined to the NKC receptor family,
namely CD94 (this study and Boyington et al., 1999),
NKG2D (Li et al., 2001, 2002; McFarland et al., 2003;
Wolan et al., 2001), CD69 (Natarajan et al., 2000), and Ly49
(Tormo et al., 1999). NKG2A is most structurally related
to CD94 (91 Ca atoms, rmsd 1.13 A˚, 28% sequence iden-
tity), followedbymurineNKG2D (97Ca atoms, rmsd1.27 A˚,902 Immunity 27, 900–911, December 2007 ª2007 Elsevier Inc26.7% sequence identity); Ly49A (93 Ca atoms, rmsd
1.29 A˚, 28.9% sequence identity); human NKG2D (95 Ca
atoms, rmsd 1.44 A˚, 22.4% sequence identity); and
CD69 (94 Ca atoms, rmsd 1.74 A˚, 26.7% sequence iden-
tity). The structural comparisons reveal that despite the
low sequence identity, the overall fold, which includes
the two b sheets, the a1 helix, and the positioning of the
three canonical C-type lectin disulfide bonds, is well con-
served. The largest area of structural divergence between
NKG2A and the other NKC receptors lies at the dimeriza-
tion site, which includes the N-terminal region, as well as
the presence or orientation of the a2 helix, and the loops
that are implicated in ligand recognition (Figure 1). For ex-
ample, in comparing the structures of NKG2A and CD94,
the major structural differences correspond to the a2 helix
and loop 3 (residues 160A–171A), which is replaced by
a long and extended loop in CD94 (residues 97B–114B);
loop 4 (residues 179A–186A), which points toward loop
5 (186A–207A) in NKG2A and away from loop 5 in CD94;
and loop 5 itself, which, although long and flexible in
both NKG2A and CD94, is structurally dissimilar (Figure 1).
Accordingly, the NKG2A fold resembles CD94 and other.
Immunity
The CD94-NKG2 Receptor FamilyFigure 2. The CD94-NKG2A Heterodimer
(A) Ribbon representation of the overall struc-
ture of the heterodimer with NKG2A shown in
purple, CD94 in green, and the interchain disul-
fide in yellow.
(B) Surface representation of the dimer inter-
face highlighting the extensive interactions
between the two subunits. Residues forming
hydrogen bonds are shown in cyan, salt bridge
partners are shown in red and blue, the cyste-
ines that form the interchain disulfide are
colored yellow, and residues involved in hydro-
phobic contacts are colored green.
(C and D) The two sites of interaction are
labeled and shown in detail in (C) site 1 and (D)
site 2. In these views, NKG2A residues in-
volved in contacts are colored red and the cor-
responding CD94 residues are shown in cyan.NKC receptors, with the largest structural differences
residing in areas that interact with ligand and the dimeriza-
tion interface (Figures 1 and 2).
Heterodimeric Assembly
NKG2A, and closely related members of the NKG2 family,
form obligate heterodimers with CD94 on the cell surface,
whereas structurally relatedNKC-encoded receptors such
as NKG2D, NKR-P1, CD69, and the Ly49 receptors are
all cotranslationally assembled as homodimers (Sawicki
et al., 2001). Accordingly, the CD94-NKG2A structure
provides insight into the specificity of heterodimer for-
mationwithin theCD94-NKG2 family. CD94-NKG2A forms
an elongated dimer, with dimensions 753 423 38 A˚, and
the two subunits are related by an almost perfect 2-fold
(175) (Figure 2). The dimer interface is large, comprising
approximately 1500 A˚2 of buried surface area (BSA).
The interface shows good shape complementarity (SC
index = 0.6) and is dominated by nonpolar interactions
that comprise 2/3 of the interface (Figure 2B; Table S1
available online). The hydrophobic interactions are cen-
trally located, whereas the two salt bridges (Glu161A and
Lys135A salt-bridged to Lys64B and Asp106B, respec-
tively) are on the periphery of the interface (Figures 2CImand 2D). Themode of CD94-NKG2A dimerization includes
main chain H-bonding between the respective b1 strands,
creating an extended 6-stranded antiparallel b sheet at
the core of the dimer interface (Figure 2). The CD94-
NKG2A interface shares some features with the NKC ho-
modimers, including a large buried surface area (ranging
from 1220 A˚2 in CD94 to 2800 A˚2 in human NKG2D) that
exhibits high shapecomplementarity, theextendedcentral
b sheet, and a large number of hydrophobic contacts.
Nevertheless, the relative juxtapositioning of the subunits
between the homodimeric NKC receptors and CD94-
NKG2A dimers was variable; for example, although the
CD69 dimer (Natarajan et al., 2000) was the most similar
(0.3), the Ly49A homodimer (Tormo et al., 1999) deviated
by 36.5 when compared to CD94-NKG2A (Figure S1).
Despite the structural homology between NKG2A and
CD94, the dimer interface is asymmetric, as a result of
structural differences between these subunits residing at
the interface. Accordingly, the mode of CD94-NKG2A
dimerization is distinct from the symmetric homodimeric
NK receptors. There are two distinct stretches of primary
structure within NKG2A, which we term site 1 and site 2,
that participate in mediating contacts at the dimer inter-
face, and these sites form a continuous interaction surfacemunity 27, 900–911, December 2007 ª2007 Elsevier Inc. 903
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The CD94-NKG2 Receptor Familywithin the heterodimer. Site 1, which spans residues
114A–135A, includes the N-terminal region that extends
toward the corresponding region in CD94 (residues 58B–
70B). This cysteine-rich region of the dimer contains the
intermolecular disulfide bond (Cys116A to Cys59B), which
is consistent with the observation of an intermolecular di-
sulfide bond via SDS-PAGE analysis. Cys116A is shielded
largely from solvent, whereas Cys59B is more solvent
accessible, yet partly occluded. Centered on the b1 strand
pairing is a small hydrophobic cluster that includes Val66B
and Tyr68B and Ile124A and Tyr126A. This hydrophobic
cluster merges into site 2, where residues (spanning resi-
dues 165A to 170A) located at the C-terminal region of the
a2 helix of NKG2A play a central role interacting with res-
idues 107B–110B from CD94. Phe165A interacts with
Val66B; Ile168A interacts with side chains of Ile75B,
Ser77B, and Tyr115B; Ile169A interacts with Phe107B
and Met108B; and Ser170A and Pro171A interact with
Ser110B. Although the site 1 interaction is relatively well
conserved between CD94-NKG2A and the homodimeric
NKC receptors, site 2 differs with the a2 helix that interacts
with the long and extended loop in CD94, varying in length
and orientation in comparison to other NKC receptors. In
summary, the data indicate that asymmetric interactions
drive the heterodimeric assembly of the receptor.
The NKG2 Receptor Family
The NKG2 receptor family comprises NKG2A, -2B, -2C,
-2D, -2E, -2F, and -2H. Of these, only NKG2D and
NKG2F are incapable of pairing with CD94 in vitro.
NKG2D functions as a homodimer and shares little se-
quence homology with the other NKG2 family members
(McFarland et al., 2003; McFarland and Strong, 2003;
Wu et al., 1999). NKG2F has a truncated ectodomain rel-
ative to the other members of this family and, although it
can associate with DAP12, the function of this isoform cur-
rently remains unknown (Kim et al., 2004). The remaining
members of this family, NKG2C, NKG2E, and NKG2H,
exhibit high sequence identity with NKG2A in the C-type
lectin domain (92% and 80%, respectively), suggesting
a common mode of assembly with CD94. Consistent
with this, 15 of the 18 dimerization contacts are conserved
across NKG2A, NKG2B, NKG2C, and NKG2E (Figure 3).
Despite the high sequence identity between CD94-
NKG2A and CD94-NKG2C, there is an approximate
6-fold difference in the affinity for HLA-E (Kaiser et al.,
2005; Vales-Gomez et al., 1999). To understand the struc-
tural basis for this affinity differential, the amino acids that
differ between NKG2A and NKG2Cweremapped onto the
structure of CD94-NKG2A. Two of these amino acids map
to the putative HLA-E binding site, position 197 in loop 5
(Glu in NKG2A, Lys in NKG2C) and position 225 within
loop 7 (Ile in NKG2A, Met in NKG2C). In addition, a cluster
of different amino acids reside at the top of themolecule at
the CD94-NKG2A interface (Ser167, Ile168, Ile169, and
Ser170 in NKG2A compared with Ala165, Ser166,
Ile167, and Leu168 in NKG2C; Figure 3B). Thus, the posi-
tioning of residues that differ betweenNKG2A andNKG2C
in the heterodimer interface raises the possibility that the904 Immunity 27, 900–911, December 2007 ª2007 Elsevier Indifferences between CD94-NKG2A and CD94-NKG2C in
their affinity for HLA-E may result from indirect effects of
the NKG2 subunit on the conformation of CD94.
Substitutions to P8 Impact on the Affinity
of CD94-NKG2A for HLA-E
The interaction of CD94-NKG2 receptors with HLA-E
bound to the leader sequence peptides derived from
MHC class I (residues 3–11) is sensitive to changes in the
C-terminal region of the peptide and in particular P8 (Kai-
ser et al., 2005; Miller et al., 2003; Vales-Gomez et al.,
1999). However, previous studies have largely been con-
fined to the substitution of a small number of hydrophobic
residues that are naturally found at this position in the
leader sequences of class I molecules (residue 10 of
MHC-I). Hence, the tolerance of the CD94-NKG2A recep-
tor for less conservative substitutions at position P8 re-
mains unknown. Consequently, we systematically made
substitutions at this position, refolded these peptides
with HLA-E, and then assessed their impact on the affinity
for CD94-NKG2A by surface plasmon resonance (SPR;
Table S2, Figure S2). By using this approach, we consid-
ered that less than a 3-fold change in affinity was insignif-
icant, a 3- to 8-fold indicated a moderate effect, and
>8-fold indicated a significant effect on the interaction.
Consistent with previous findings, HLA-E complexed to
the peptide corresponding to the leader sequence peptide
derived from HLA-G-bound CD94-NKG2A with an affinity
of 0.94 mM (Kaiser et al., 2005; Vales-Gomez et al., 1999).
The kinetics of the interaction were too rapid to allow
accurate determination of the kinetic rate constants.
Although this peptide has a Phe at P8, the amino acids
present in this position of other class Ia-encoded leader
sequence peptides are predominantly the hydrophobic
residues Ile, Leu, or Val. Substitution of P8-Phe for each
of these smaller hydrophobic residues decreased the af-
finity of HLA-E for CD94-NKG2A (Table S2). Specifically,
the complexes with P8-Leu and P8-Val peptides bound
with a 90% reduction in affinity; the P8-Ile substitution
had amodest effect (2.97 mM); whereas the P8-Ala substi-
tution, a residue not typically present in class I leader
sequences, resulted in a 97% decrease in affinity. Simi-
larly substitution with either Tyr or Lys at P8 (neither of
which are present in the leader sequences of MHC-I)
also reduced the affinity of the interaction to 19 mM and
34mM, respectively, which indicated that polar and charged
residues are not tolerated at position P8. In summary,
the data suggests that there is a preference for a bulky,
solvent-exposed hydrophobic residue at this position for
optimal interaction with CD94-NKG2A.
Alanine Scanning Mutagenesis of HLA-E
The interaction with the CD94-NKG2 receptors was un-
likely to be solely mediated by peptide contacts, so we
made 16 individual alanine-scanning mutations in HLA-E
that were subsequently refolded with the VMAPRTLFL
peptide and assessed their ability to interact with CD94-
NKG2A (Table 2). With the exception of the Lys146mutant
that failed to refold, all mutants refolded with similar yieldsc.
Immunity
The CD94-NKG2 Receptor FamilyFigure 3. The NKG2x Family
(A) Sequence alignment of NKG2Awith other NKG2 receptors and CD94. Sequence alignments of the stem (italics) and CTLD ectodomains of NKG2x
and CD94, showing intrachain cysteines in purple. Residues conserved between NKG2A, -2B, -2C, -2E, and -2H are indicated by the dashes. Sub-
stitutions between NKG2A and -2C isoforms that could account for the difference in affinity for HLA-E are highlighted in yellow. Secondary structures
for NKG2A, NKG2D, and CD94 are shown above the sequences, with cylinders representing a helices and arrows representing b sheets. Residues
involved in homodimerization (NKG2D) or heterodimerization (NKG2A andCD94) are shown in cyan, with interchain cysteines colored in red. Asterisks
indicate putative HLA-E binding sites on CD94 and NKG2A.
(B) Ribbon representation of CD94-NKG2A heterodimer with the residues that differ between NKG2A and NKG2C shown in yellow and the interchain
disulfide bond shown in red.to wild-type HLA-E. As expected, the Thr214 mutation in
the a3 domain of HLA-E had nomarked effect on the affin-
ity of the interaction with CD94-NKG2A (Table 2). Substi-
tution of many of the exposed charged residues (Arg62,
Asp69, Glu89, Arg108, Asp149, and Glu154) in both the
a1 and a2 helices of HLA-E also had little effect on its
affinity for CD94-NKG2A (Figure 4). Similarly, mutation ofImHis155, which makes contact with P5-Arg, had little effect
on the affinity of HLA-E for CD94-NKG2A. However, muta-
tion of Arg65, Arg79, and Glu166 had a modest impact on
the affinity of the interaction. In contrast, mutation of
Arg75 and Val76 that are proximal to P8-Phe had a sub-
stantial effect on the interaction with the Val76 mutation
resulting in a 90% decrease in the affinity of themunity 27, 900–911, December 2007 ª2007 Elsevier Inc. 905
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The CD94-NKG2 Receptor Familyinteraction, and the Arg75 mutation essentially abrogated
binding altogether (Table 2, Figure 4A). Mutation to Ala of
either Gln72 or Glu152 that flank the P5-Arg also had
a marked impact on recognition by CD94-NKG2A result-
ing in dissociation constants of 17.9 mM and 23.1 mM,
respectively. Mutation of Asp162, a residue that is located
on the a2 helix but does not make peptide contacts,
decreased the affinity for CD94-NKG2A to 12.9 mM. Col-
lectively, the mutagenesis data revealed that residues
from both the a1 and a2 helices are critical for recognition,
although the data were consistent with the a1 helix playing
a more prominent role in the interaction than the a2 helix
of HLA-E.
Alanine Scanning Mutagenesis of CD94-NKG2A
Although mutagenesis of HLA-E provided insight into the
likely diagonal-mode of docking of the CD94-NKG2A re-
ceptor on HLA-E, the orientation of the CD94-NKG2A
with respect to HLA-E was ambiguous; moreover, the rel-
ative contributions of the CD94 and NKG2A subunits to
the interaction with HLA-E was unclear. To address these
issues, a mutagenesis approach was again employed in
which exposed residues on either CD94 or NKG2A were
mutated to Ala and the affinity of the interaction between
mutant receptor and HLA-E determined. In total, 21
CD94-NKG2A mutants were made, all of which refolded
with an efficiency comparable to that of the wild-type
receptor. Although mutation of CD94 residues Gln79B,
Thr146B, Asn148B, and Asn158B had no substantial
Table 2. Affinity of Mutant HLA-E-Peptide Complexes
for CD94-NKG2A
HLA-E Mutant KD (mM) CD94-NKG2A
Wild-type 0.94 ± 0.11
R62A 1.75 ± 0.45
R65A 3.05 ± 0.29
D69A 1.85 ± 0.84
Q72A 17.9 ± 4.05
R75A >207
V76A 9.22 ± 0.78
R79A 5.23 ± 0.78
E89A 1.02 ± 0.45
R108A 1.69 ± 0.12
D149A 1.45 ± 0.13
E152A 23.13 ± 2.16
E154A 2.12 ± 0.12
H155A 1.76 ± 0.14
D162A 12.87 ± 2.20
E166A 3.08 ± 0.23
T214A 1.44 ± 0.06
Data are represented asmeans ± standard error of 2–5 exper-
iments with independent preparations of refolded proteins.906 Immunity 27, 900–911, December 2007 ª2007 Elsevier Incimpact on the binding of CD94-NKG2A to HLA-E, a num-
ber of other mutations markedly reduced the affinity of the
interaction (Table 3, Figure 4B). Notably, mutation of CD94
residues Gln112B and Phe114B, which are located at the
C-terminal end of loop 3, abrogated binding to HLA-E.
Similarly, mutation of either Asn160B or Leu162B, which
are located at the C terminus of loop 6 and the beginning
of the b6 strand, respectively, also abolished recognition
of HLA-E. Moreover, the observation that mutation of the
adjacent residues Asp163B and Glu164B also resulted
in a greater than 90% reduction in affinity further sug-
gested an important role for the b6 strand of CD94 in the
interaction with HLA-E.
In contrast, nomutations of the NKG2A subunit resulted
in a dramatic change in the affinity of the receptor for HLA-
E (Table 3). Specifically, of the 10 mutants generated,
none resulted in a 5-fold or greater decrease in the affinity
of CD94-NKG2A for HLA-E, and only changes in Arg137A
located in the b2 strand and Gln212A and Arg215A lo-
cated at the end of the b5 strand and the adjacent loop re-
sulted in modest decreases in the affinity of the interaction
(Figure 4B). Thus, the CD94-NKG2A mutagenesis data
demonstrate that CD94 plays a crucial role in providing
energetically critical contacts whereas the role of
NKG2A appears to be more limited.
A Model of the CD94-NKG2A Interaction
with HLA-E
Based on the mutagenesis data and the structures of the
nonliganded CD94-NKG2A receptor and the HLA-E mole-
cules, we constructed a model of the ternary CD94-
NKG2A-HLA-E complex, with the NKG2D-NKG2D ligand
complexes as a template that is broadly consistent with
earlier models that utilized the crystallographic dimer of
CD94 and the NKG2D-MICA structure (Figure 4C). Our
model suggests that the CD94-NKG2A docks in a mode
that is diagonal to the long axis of the HLA-E Ag-binding
cleft, such that the CD94 subunit is positioned mostly
over the a1 helix and NKG2A over the a2 helix. This orien-
tation is based on the observations that themajority of res-
idues in HLA-E that are critical for the interaction are in the
a1 helix flanking P5 and P8 and that there is ‘‘hotspot’’ in
CD94 comprised of residues 112 and 114 together with
160 and 162–164 (Figure 4B). Thus, CD94 is predicted to
mediate the contacts with the peptide, in agreement
with the observation that substitutions at the C terminus
of the peptide affect the interaction of all CD94-NKG2
receptors with HLA-E in a similar manner (Kaiser et al.,
2005). This is also consistent with structural analyses by
Li et al. (2001) and Kaiser et al. (2005) and themutagenesis
data from Wada et al. (2004). Indeed, consistent with our
mutagenesis data, these studies identified a hydrophobic
patch on HLA-E comprised of Ile73, Val76, and the side
chain of P8, which was proposed to interact with a hydro-
phobic region on CD94 (Phe114, Leu162).
Further insight into the mode of CD94-NKG2-HLA-E
recognition is provided by the observation that there is
a 6-fold difference in affinity in the interaction between
CD94-NKG2A and CD94-NKG2C (Kaiser et al., 2005;.
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(A and B) Individual HLA-E (A) and CD94-NKG2A (B) residues were mutated, and the affinity of the interaction between the proteins was measured by
surface plasmon resonance. Residues that had a major influence on binding when mutated are shown in red, residues with a minor influence are in
yellow, and residues that did not alter affinity for binding whenmutated are shown in blue. The positioning of the residues that had the largest effect on
binding affinity suggests a diagonal docking mode of CD94-NKG2A onto HLA-E (black line). CD94 and NKG2A subunits are colored light green and
light blue, respectively.
(C) Model of CD94-NKG2A recognition of HLA-E. CD94-NKG2A docking on HLA-E-VMAPRTLFL was modeled on the NKG2D-MIC-A structure
(1HYR). A surface representation of CD94-NKG2A is shown in purple (NKG2A) and green (CD94), with the a helices of HLA-E in red and the
VMAPRTLFL peptide in white. Residues that differ between NKG2A and NKG2C are colored yellow. CD94-NKG2A binding hotspots on HLA-E, as
identified by mutagenesis, are shown as red spheres.Vales-Gomez et al., 1999). Of the sequence differences
between NKG2A and NKG2C that are located within our
candidate-docking site, position 197 was shown not to
be a critical residue, because mutation of Glu197 of
NKG2A to Lys that is present in NKG2C had little impact
on affinity for HLA-E (Kaiser et al., 2005). Our crystallo-
graphic data suggest that the cluster of amino acid vari-
ability between NKG2A and NKG2C at the C-terminal
end of the a2 helix of the NKG2 subunit was likely to play
a key role, either directly by contacting HLA-E, or indi-
rectly, by altering the conformation of the neighboring sur-
face-exposed CD94 loop that, in accord with our model,
interacts with the HLA-E. Consequently, to more formally
address the impact of these differences on recognition of
HLA-E, mutant CD94-NKG2A molecules were generated
in which residues 167–170 in NKG2A (Ser-Ile-Ile-Ser)
were replaced with those in NKG2C (Ala-Ser-Ile-Leu)
(see Figure 3) or where residue 163, a Met in NKG2A,
was exchanged for an Ile that is present at this position
in NKG2C. Although the Met163Ile mutation had littleImimpact on the interaction with HLA-E, the presence of
the NKG2C sequences in the a2 helix of NKG2A de-
creased the affinity of the interaction with HLA-E by 83%
(Table 3). To confirm that substitutions in the a2 helix of
NKG2A were responsible for the differences in the affinity
for CD94-NKG2A and -NKG2C for HLA-E, we replaced
residues 161 and residues 165–168 with the correspond-
ing amino acids fromNKG2A.Consistent with the previous
data, the Ile161Met mutation did not markedly impact on
the interaction between CD94-NKG2C and HLA-E. How-
ever, replacement of NKG2C residues 165–168 (Ala-Ser-
Ile-Leu) with the corresponding residues in NKG2A
(Ser-Ile-Ile-Ser) resulted in an increase in the affinity of
the interaction to 1.31 mM, a value similar to that observed
for the HLA-E-CD94-NKG2A interaction. Together, these
data not only provide insight into the interactions respon-
sible for the different affinities of CD94-NKG2A and
-NKG2C for HLA-E but also provide further support for
the model of the interaction between CD94-NKG2 recep-
tors and HLA-E.munity 27, 900–911, December 2007 ª2007 Elsevier Inc. 907
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Proteins with a C-type lectin fold play a prominent role in
innate immunity, with soluble members providing innate
defenses in mucosal fluids, whereas membrane-bound
C-type lectins, such as the NKC receptor family, play
a central role in the elimination of tumor and virus-infected
cells (Kogelberg and Feizi, 2001). The NKC receptors are
often found as homodimers as a result of homotypic
Table 3. Affinity of Mutant CD94-NKG2A Complexes
for HLA-E
Mutant KD (mM)
Wild-type 1.23 ± 0.12
CD94 Mutant
Q79A 1.02 ± 0.09
Q112A NB
F114A NB
T146A 1.23 ± 0.07
N148A 0.77 ± 0.07
N158A 0.38 ± 0.04
N160A NB
L162A NB
D163A 17.24 ± 0.85
E164A 13.22 ± 0.84
D168A 4.76 ± 0.44
NKG2A Mutant
R137A 4.13 ± 0.23
S172A 1.84 ± 0.16
D200A 0.79 ± 0.12
D202A 1.39 ± 0.12
Q212A 3.83 ± 0.46
V213A 1.95 ± 0.13
R215A 4.32 ± 0.29
K217A 3.12 ± 0.17
Q220A 2.88 ± 0.44
S223A 1.46 ± 0.09
Mutant
NKG2C wt 6.88 ± 0.46
NKG2C I161M 6.62 ± 0.79
NKG2C 165-168SIIS 1.31 ± 0.18
NKG2A wt 1.54 ± 0.12
NKG2A M163I 1.46 ± 0.13
NKG2A 167-170ASIL 8.92 ± 0.85
Data are represented asmeans ± standard error of 2–5 exper-
iments with independent preparations of refolded proteins.
NB: The interaction was tooweak to allow an estimation of the
KD based on the concentration range of analyte.908 Immunity 27, 900–911, December 2007 ª2007 Elsevier Incinteractions within the C-type lectin domain as well as in-
teractions with the membrane-proximal regions of the re-
ceptors. However, the CD94-NKG2 family is atypical,
preferentially forming heterodimeric receptors. This allows
for a degree of biological adaptability such that a single
ligand can induce either activating or inhibitory signals de-
pending on the particular NKG2 subunit associated with
CD94 and/or the relative levels of expression of the vari-
ous NKG2 isoforms (Brooks et al., 1997; Carretero et al.,
1997; Lazetic et al., 1996).
Although CD94 has the potential to form homodimers
(Boyington et al., 1999), they exhibit poor shape comple-
mentarity and a low BSA at the dimer interface and their
functional significance remains unclear. In contrast, we
have observed no evidence of soluble NKG2A homo-
dimers in in vitro refolding experiments (unpublished
observations), and our attempts to generate an NKG2A
homodimer in silico based on the CD94-NKG2A structure
resulted in steric clashes with the a2 helix, which also
would likely preclude the formation of the intermolecular
disulfide bond. The data suggest that heterodimer forma-
tion is largely driven by interactions within the respective
C-type lectin domains, which is evident in the extensive
hydrophobic interface between these domains. Consis-
tent with this, Lieto et al. (2006) identified an alternatively
spliced form of CD94 that lacks 21 amino acids from the
stem region that preferentially pairs with NKG2B (which
itself is an alternatively spliced form of NKG2A that lacks
18 amino acids in the stem region) (Lieto et al., 2006). Col-
lectively, this suggests that although the stalk regions of
theCD94 andNKG2 subunitsmay contribute to the forma-
tion of the heterodimeric receptor, the driving forces for the
assembly of CD94-NKG2 heterodimers are likely to be the
innate attraction of the CD94 and NKG2 C-type lectin
domains.
Given that NKG2A is structurally homologous to CD94
and other NKC receptors, a priori it was unclear why it
would preferentially pair with CD94. The structure of the
CD94-NKG2A heterodimer reveals that the mode of di-
merization is driven not only via an intermolecular disulfide
bond but also by asymmetric interactions. The asymmetry
at the CD94-NKG2A interface is largely a result of the
a2 helix of NKG2A interacting with the corresponding ex-
tended loop region of CD94. The high sequence identity
among the NKG2 isoforms, as well as interspecies con-
servation, suggests that this mode of heterodimerization
is conserved across the CD94-NKG2 family.
CD94-NKG2A is highly specific for HLA-E in complex
with peptides derived from the leader sequence of MHC
class I molecules (Borrego et al., 1998; Brooks et al.,
1999; Llano et al., 1998; Vales-Gomez et al., 1999). The
data here highlight the importance of P8 side chain for rec-
ognition of HLA-E by CD94-NKG2A. The observation that
HLA-E bound to peptides with Ala, Tyr, or Lys at P8 inter-
acts with CD94-NKG2A with low affinity suggests a role
for this residue in governing the specificity of the interac-
tion. Moreover, a Val for Ile substitution at P8 resulted in
a 27% reduction in the affinity of CD94-NKG2A for HLA-E,
suggesting that the avidity of the interaction between.
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vary substantially, not only as a function of the amount of
HLA-E expressed at the cell surface but in amanner that is
dependent on the HLA genotype of the individual.
To provide insight into the footprint CD94-NKG2A
adopted on HLA-E and the relative importance of both
CD94 and NKG2A in this interaction, we undertook an
alanine-scanning approach, assessing the impact of mu-
tations on the affinity of the interaction between CD94-
NKG2A and HLA-E. Mutation of Gln72, Arg75, Val76,
Glu152, and Asp162 of HLA-E all markedly impaired the
affinity of the interaction with CD94-NKG2A, confirming
earlier observations by Wada et al. (2004), who showed
that mutations at residues 72, 75, and 162 largely abro-
gated binding of HLA-E tetramers to cells that express
CD94-NKG2A.
Mutagenesis of CD94-NKG2A suggested that CD94
played a much more prominent role in the interaction
with HLA-E than NKG2A, which was largely attributable
to an energetic hotspot that includes residues Gln112,
Phe114, Asn160, Leu162, Asp163, and Glu164 of CD94.
Accordingly, based on (1) the structural homology be-
tween the CD94-NKG2A-HLA-E interaction and that of
NKG2D with MIC-A (Li et al., 2001), (2) mutagenesis data
on HLA-E (Wada et al., 2004), (3) mutagenesis data on
CD94-NKG2A, and (4) the observation that changes in
peptide sequence impacted equally on CD94-NKG2A,
-C, and -E (Kaiser et al., 2005), evidence suggested that
the CD94 subunit was located primarily over the a1 helix
of HLA-E making contact with the exposed side chain at
P8. The data here provide direct support for a model in
which the energetic hotspot bounded by residues 73,
75, 76 of HLA-E together with the side chain of P8 interact
with the residues that comprise the energetic hotspot of
CD94. Moreover, there appears to be a degree of comple-
mentarity between these regions of HLA-E and CD94 that
would allow for hydrophobic interactions between resi-
dues Val76 of HLA-E together with Phe at P8 of the pep-
tide with Leu112 and Phe114 of CD94. There is also a
degree of charge complementarity here as the energetic
hotspot on HLA-E is bounded by Arg75 and Arg79,
whereas this region of CD94 contains an Asp and Glu at
positions 163 and 164, respectively. Our data also provide
insight into the basis for the difference in affinity between
CD94-NKG2A and CD94-NKG2C for HLA-E, whereby
NKG2 residues at the CD94-NKG2 interface appear to
determine this affinity differential. Collectively, our data
reveals the detailed architecture of the CD94-NKG2A het-
erodimer and provides insight into the basis of the central
innate interaction between this NK heterodimer and the
class Ib molecule HLA-E.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification of CD94-NKG2A
The recombinant baculovirus coexpression of CD94 and NKG2A was
achieved by cloning residues 34–179 of CD94 and 100–233 of NKG2A
into the BamHI and PstI sites and the SphI and XmaI sites of the pFast-
Bac Dual vector, respectively. This allowed incorporation of the CD94
and NKG2A into the bacmid DNA via transposition of pFastBac CD94-NKG2A into DH10Bac E. coli (Invitrogen). The sequence of the pFast-
Bac CD94-NKG2A plasmid was verified via sequencing, and the cor-
rect incorporation of the CD94-NKG2A cassette into the bacmid
DNA was verified via PCR. The viral titer of the resulting bacmid was
then amplified in Sf9 insect cells (Invitrogen) grown at 27C with shak-
ing at 120 rpm, and the virus located in the supernatant was separated
from the insect cells via centrifugation at 500 3 g in an Eppendorf
benchtop centrifuge. The expression of CD94-NKG2A was achieved
typically in 43 1 L flasks of Hi-5 insect cells at 2.0 3 106 cells/ml (Invi-
trogen) by infection with the amplified viral stocks for approximately
68–72 hr at 27C with shaking at 120 rpm. All Sf9 and Hi5 insect cells
were grown at 27C inGIBCOSF900 II serum-freemedia (Invitrogen) in
the presence of 10 mg/ml Gentamycin.
The CD94-NKG2A protein was secreted into the media by the Hi5
cells, and separation of the secreted protein from whole cells was
achieved via centrifugation at 500 3 g followed by centrifugation at
50003 g in a SLC-6000 Beckman rotor for further purification. The su-
pernatant containing CD94-NKG2A was then filtered through a 0.2 mm
filter and concentrated to 1 L, and buffer was exchanged into TBS
(10mMTris-HCl [pH 8.0], 150mMNaCl) with Tangental flow apparatus
(624S model, Waton Marlow). The supernatant was then applied to
pre-equilibrated Nickel affinity sepharose (GE Healthcare) and eluted
with 300mM Imidazole in TBS according to manufacturer instructions.
The eluted CD94-NKG2A was then further purified on a Superdex 200
16/60 (GE Healthcare) gel filtration column operating on an Akta Puri-
fier system (GE Healthcare) prior to removal of the His6 affinity tag
via Enterokinase (Genscript, USA) at 4C overnight according to
manufacturer’s instructions. The cleaved His6 tag was separated
from CD94-NKG2A by passing over Nickel sepharose. The unbound
CD94-NKG2A was then further purified on a MonoQ column with
a 0%–30%gradient of 1MNaCl in 10mMTris-HCl (pH 8.0). The result-
ing protein was then quantified against BSA standards and absor-
bance for further use.
For expression with E. coli, the extracellular domains of CD94 and
NKG2A (CD94 residues 40–179, NKG2A residues 110–223) were
cloned separately into the modified pET-30 expression vector, and
the proteins were solubilized from inclusion bodies after expression
in E. coli as above. Inclusion bodies were mixed 1:2 CD94:NKG2A
and also refolded by dilution as described for the KK50.4 TCR (Hoare
et al., 2006). CD94-NKG2A complexes were purified by anion
exchange and gel filtration chromatography, prior to an additional
purification step by MonoQ.
Crystallization, Data Collection, Structure Determination,
and Refinement
Crystals of CD94-NKG2A heterodimer were grown in 1.0–1.4 M triso-
dium citrate, 0.1 M HEPES (pH 6.7–7.3). The crystals were flash frozen
at 100K with 15% glycerol as a cryoprotectant. A 2.5 A˚ data set was
collected at the IMCA beamline (Advanced Photon Source, Chicago)
with a Quantum 210 CCD. The data were processed and scaled with
programs from the CCP4 suite (CCP4, 1994). The crystal structure of
the heterodimer was solved by molecular replacement implemented
by Phaser (McCoy et al., 2005) with CD94 as the search model. For
NKG2A, all differences in the search model were mutated to alanine,
and surface loops were removed. The progress of refinement was
monitored by the Rfree value (5% of the data) with neither a s nor
a low-resolution cut-off being applied to the data. The structure was
refined with Refmac (CCP4, 1994) and simulated annealing imple-
mented in CNS (Bru¨nger et al., 1998), interspersed with rounds of
model building in ‘‘Coot’’ (Emsley and Cowtan, 2004). For the data
collection and refinement statistics, see Table 1.
Mutagenesis and Surface Plasmon
Resonance Measurements
Production of Soluble, Recombinant Proteins
cDNA encoding the extracellular domain of wild-type HLA-E*0103 and
human b2-microglobulin (b2m) were cloned into a modified pET-30 ex-
pression vector (Boyington et al., 2000). After expression in the E. coliImmunity 27, 900–911, December 2007 ª2007 Elsevier Inc. 909
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The CD94-NKG2 Receptor Familystrain BL21 (DE3) pLysS, the proteins were solubilized from inclusion
bodies and refolded with synthetic peptides (GL Biochem, Shanghai,
China) as previously described (Hoare et al., 2006). The resulting
HLA-E-peptide complexeswere purified by anion exchange and gel fil-
tration chromatography. Site-directed mutations were generated by
the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla,
CA), and the sequence of the mutated cDNA was verified by DNA se-
quencing. The residues chosen for mutagenesis were surface exposed
residues and thus were considered unlikely to affect stability of either
the HLA-E complex or the CD94-NKG2A receptor. All of the mutants
elutedwith a similar gel filtration profile to thewild-type protein. Mutant
HLA-E molecules were also assessed for their ability to bind to both
a pan-anti-HLA class I specific mAb (w6/32) and anti-human b2-micro-
globulin by capture ELISA. At the same concentrations, all mutants
gave a similar OD reading to wild-type HLA-E. The conformational in-
tegrity of mutant CD94-NKG2A receptors was verified by ELISA with
conformationally sensitive mAb specific for either CD94 or NKG2A.
BIAcore Analysis
The interaction between soluble, recombinant HLA-E and CD94-
NKG2A was analyzed by surface plasmon resonance (SPR) with a
BIAcore 3000 instrument (BIAcore, Piscataway, NJ). All experiments
were performed at 25C in a buffer containing 10 mM HEPES (pH
7.4), 150 mM NaCl, and 0.005% Surfactant P-20 (BIAcore). CD94-
NKG2A was diluted into 10 mM sodium acetate (pH 5.5), and 500 RU
was immobilized a CM5 Sensorchip (BIAcore) by amine coupling
as recommended by themanufacturer. Each chip contained two differ-
ent preparations of immobilized CD94-NKG2A and two control
surfaces. Recombinant HLA-E was subjected to size exclusion chro-
matography immediately prior to analysis, and the concentration of
purified protein was estimated with a Bradford assay. It was then seri-
ally diluted from 20 mM to 0.05 mM in HBS and injected simultaneously
over the test and control surfaces at a flow rate of 40 mL/min. All mea-
surements were taken in duplicate and results from at least two inde-
pendent experiments were analyzed. After subtraction of data from
control flow cells, the interactions were analyzed with the BIAevalua-
tion software version 4.1 (BIAcore) and steady-state KD values were
derived from the general fit option of the software package.
Supplemental Data
Two figures and two tables are available at http://www.immunity.com/
cgi/content/full/27/6/900/DC1/.
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